Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Obstetrics

How Accurate is NIPT for 22q11.2 Deletion Syndrome?

At a Glance

A high-risk NIPT result for 22q11.2 deletion syndrome (DiGeorge syndrome) is not a diagnosis. The test has a high false positive rate of 47% to 88%. To confirm if your baby actually has the condition, diagnostic testing like an amniocentesis or a postnatal blood test is required.

In this answer

5 sections

01

How Accurate is NIPT for 22q11.2 Deletion?

02

What Causes a False Positive?

03

The Next Step: Genetic Counseling

04

Confirming the Results: Diagnostic Testing

05

Why Screen at All?

Getting a “high risk” result for 22q11.2 deletion syndrome (also known as DiGeorge syndrome) on a prenatal blood test is frightening, but the most important thing to know is this: your baby does not definitely have the condition [1][2]. Non-Invasive Prenatal Testing (NIPT), also known as cell-free DNA (cfDNA) screening, is a screening tool, not a diagnostic test [1][3]. It can only tell you if your baby has a higher chance of having the syndrome, but it cannot give you a definitive answer [2][4].

How Accurate is NIPT for 22q11.2 Deletion?

While NIPT is highly accurate for conditions like Down syndrome, its accuracy for microdeletions (conditions caused by a tiny missing piece of a chromosome) like 22q11.2 is much lower.

The most helpful statistical concept to understand your result is the Positive Predictive Value (PPV). The PPV tells you the percentage of “high risk” results that turn out to be true positives. Recent clinical studies show that the PPV for 22q11.2 deletion syndrome ranges from roughly 12% to 53%, depending on the specific testing platform used [5][6][7].

To put this in perspective:

Chance of False Positive=100%−PPV \text{Chance of False Positive} = 100\% - \text{PPV}

If the PPV is between 12% and 53%, this means there is a 47% to 88% chance that your “high risk” result is a false positive and your baby does not have the condition [5][6].

What Causes a False Positive?

False positives happen because of how the NIPT works. The test analyzes small fragments of DNA floating in the pregnant person’s bloodstream, but this DNA actually comes from multiple sources, primarily the mother and the placenta [8][9].

A “high risk” result can occur when the baby is completely unaffected, but one of the following is true:

  • Confined Placental Mosaicism (CPM): This is a biological phenomenon where the placenta carries a genetic difference (the 22q11.2 deletion) but the fetus itself does not [9][10]. Because NIPT measures DNA shed by the placenta, it can mistakenly flag the baby as having the condition [11].
  • Maternal DNA: Occasionally, the pregnant person may have a very mild, undiagnosed case of 22q11.2 deletion syndrome [8][12]. (In adults, a “mild” case often looks like minor learning differences or easily managed calcium levels, rather than life-threatening heart defects.) The test detects the mother’s missing DNA and incorrectly flags the baby as high risk [6]. If this is suspected, your doctor can order a test for you to check your own genetics and provide peace of mind.

The Next Step: Genetic Counseling

The single most important step after receiving a high-risk NIPT result is to meet with a Genetic Counselor or a Maternal-Fetal Medicine (MFM) specialist [13][14]. Standard obstetricians may not be equipped to fully explain the nuances of microdeletion testing or your specific PPV. A specialist will help you understand your unique risks, discuss what an ultrasound can (and cannot) show, and help you navigate your options for diagnostic testing [15][13].

Confirming the Results: Diagnostic Testing

Because of the high chance of a false positive, positive screening results should be confirmed with invasive testing before making major decisions about the future of the pregnancy [2][16]. To know for sure if your baby has 22q11.2 deletion syndrome, diagnostic testing is required [1][2].

There are two primary pathways for diagnostic confirmation:

  1. Amniocentesis: An invasive procedure done during pregnancy (usually between 15 and 20 weeks) to test the amniotic fluid surrounding the baby. For 22q11.2 deletion syndrome, amniocentesis is often preferred to clarify the baby’s genetic status [17][18]. While generally safe when performed by experienced clinicians, it does carry a small risk of miscarriage [19].
  2. Chorionic Villus Sampling (CVS): A test performed earlier in pregnancy (10–13 weeks) that samples placental tissue. While CVS provides answers sooner, there is a small risk that it might only test the placental cells (which could have the deletion due to CPM) rather than the baby’s actual genetics [18][20]. If you have already had a CVS and it was positive, a follow-up amniocentesis or postnatal test might still be recommended [17].
  3. Postnatal Testing: Testing the baby’s blood immediately after birth. This completely avoids the miscarriage risks of invasive testing during pregnancy.
Diagnostic Method Timing What It Tests Risk of Confined Placental Mosaicism (CPM) Interference?
Amniocentesis 15–20 weeks of pregnancy Amniotic fluid (fetal cells) Low risk [17][18]
Chorionic Villus Sampling (CVS) 10–13 weeks of pregnancy Placental tissue High risk [18][20]
Postnatal Blood Draw After birth The baby’s blood No risk

For any of these tests, the laboratory must use a specialized technique called Chromosomal Microarray (CMA). Traditional chromosome testing (karyotyping) cannot consistently detect the tiny piece of missing DNA in 22q11.2 deletion syndrome, making CMA the required standard for clinical diagnosis [21][22].

Why Screen at All?

If the test has a high rate of false positives, it is natural to wonder why doctors offer it. Knowing that a baby truly has 22q11.2 deletion syndrome before birth allows the medical team to prepare.

A high-risk screening often prompts detailed ultrasound examinations to monitor for congenital heart defects or other associated abnormalities [23][24]. However, a normal ultrasound does not rule out the syndrome, as microscopic genetic changes require diagnostic testing to confirm, and many babies with 22q11.2 do not have visible anatomical differences on scans [1][3].

Additionally, babies born with this condition can experience hypocalcemia (dangerously low calcium levels) or require immediate cardiac care [25][26]. Early detection ensures that the right specialists, such as pediatric cardiologists, are present in the delivery room, which is associated with reduced hospital stays and lower early morbidity [25][26][6].

Common questions in this guide

What does a high risk NIPT result for 22q11.2 deletion mean?
A high risk result means your baby has a higher chance of having the condition, but it is not a definite diagnosis. Non-invasive prenatal testing is only a screening tool, and false positives for microdeletions are very common.
What is the false positive rate for 22q11.2 deletion on an NIPT?
Depending on the specific testing platform used, there is a 47% to 88% chance that a high-risk result is a false positive. This means many babies flagged as high risk do not actually have 22q11.2 deletion syndrome.
Why might an NIPT give a false positive for DiGeorge syndrome?
False positives often happen because the test analyzes DNA from the placenta, which can sometimes have genetic differences that the baby does not share. Additionally, the test might detect a very mild, undiagnosed case of the deletion in the pregnant person's own DNA.
How can I confirm if my baby actually has 22q11.2 deletion syndrome?
You can confirm a positive screening result through diagnostic testing, such as an amniocentesis during pregnancy or a blood test after birth. These tests require a specialized laboratory technique called a chromosomal microarray to definitively detect the missing genetic material.
Can a normal ultrasound rule out 22q11.2 deletion syndrome?
No, a normal ultrasound cannot completely rule out the syndrome. While doctors look for congenital heart defects on scans, microscopic genetic changes require diagnostic testing, and many babies with the condition do not show visible anatomical differences before birth.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific NIPT brand or platform was used for my screening, and what is the specific Positive Predictive Value (PPV) for that test?
  2. 2.Can you refer me to a Genetic Counselor or Maternal-Fetal Medicine (MFM) specialist to discuss my options?
  3. 3.What are the specific miscarriage risks for amniocentesis at this clinic or with the specialist who will perform it?
  4. 4.Should I consider being tested myself to rule out an undiagnosed maternal 22q11.2 deletion as the cause of this result?
  5. 5.Will you be scheduling a fetal echocardiogram (specialized heart ultrasound) to check for congenital heart defects?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Is DiGeorge Syndrome the Same as 22q11.2 Deletion?Are Live Vaccines Safe in 22q11.2 Deletion Syndrome?Can Adults With 22q11.2DS Live Independently?How Common is 22q11.2 Deletion Syndrome?How Does 22q11.2 Deletion Syndrome Affect Speech & Palate?How to Read a 22q11.2 Deletion Genetic Test ReportIs 22q11.2 Deletion Syndrome Hereditary?What Are Low Calcium Symptoms in 22q11.2 Deletion?What IEP Accommodations Are Best for 22q11.2 Deletion?What is the Life Expectancy for 22q11.2 Deletion Syndrome?Does 22q11.2 Deletion Syndrome Cause Parkinson's?What is the Schizophrenia Risk in 22q11.2DS?What Specialists Treat 22q11.2 Deletion Syndrome?

References

References (26)
  1. 1

    The Impact of Chromosomal Mosaicisms on Prenatal Diagnosis and Genetic Counseling-A Narrative Review.

    Militaru MS, Babliuc IM, Bloaje-Florică VL, et al.

    Journal of personalized medicine 2024; (14(7)) doi:10.3390/jpm14070774.

    PMID: 39064028
  2. 2

    Confined placental mosaicism and its impact on confirmation of NIPT results.

    Mardy A, Wapner RJ

    American journal of medical genetics. Part C, Seminars in medical genetics 2016; (172(2)):118-22 doi:10.1002/ajmg.c.31505.

    PMID: 27184347
  3. 3

    Application value of NIPT for uncommon fetal chromosomal abnormalities.

    Yin L, Tang Y, Lu Q, et al.

    Molecular cytogenetics 2020; (13()):39 doi:10.1186/s13039-020-00508-z.

    PMID: 32874204
  4. 4

    Efficiency of Non-Invasive Prenatal Testing in Detecting Fetal Copy Number Variation: A Retrospective Cohort Study.

    Yang L, Yang J, Bu G, et al.

    International journal of women's health 2024; (16()):1661-1669 doi:10.2147/IJWH.S479747.

    PMID: 39381715
  5. 5

    Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome.

    Dar P, Jacobsson B, Clifton R, et al.

    American journal of obstetrics and gynecology 2022; (227(1)):79.e1-79.e11 doi:10.1016/j.ajog.2022.01.002.

    PMID: 35033576
  6. 6

    Evaluating the effectiveness of routine noninvasive prenatal screening for CNVs in 22q11.2 region in a cohort of 38,495 pregnancies.

    Cong X, Hu L, Pei Y, et al.

    Scientific reports 2025; (16(1)):3922 doi:10.1038/s41598-025-33979-4.

    PMID: 41461890
  7. 7

    Performance of a targeted cell-free DNA prenatal test for 22q11.2 deletion in a large clinical cohort.

    Bevilacqua E, Jani JC, Chaoui R, et al.

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2021; (58(4)):597-602 doi:10.1002/uog.23699.

    PMID: 34090308
  8. 8

    A false-positive result at non-invasive prenatal testing due to maternal 17p12 microduplication.

    Chen CP, Chen SW, Wu PS, et al.

    Taiwanese journal of obstetrics & gynecology 2022; (61(3)):532-534 doi:10.1016/j.tjog.2022.03.037.

    PMID: 35595453
  9. 9

    Unexpected finding of uniparental disomy mosaicism in term placentas: Is it a common feature in trisomic placentas?

    Van Opstal D, Diderich KEM, Joosten M, et al.

    Prenatal diagnosis 2018; (38(12)):911-919 doi:10.1002/pd.5354.

    PMID: 30187503
  10. 10

    Analysis of the accuracy of Z-scores of non-invasive prenatal testing for fetal Trisomies 13, 18, and 21 that employs the ion proton semiconductor sequencing platform.

    Tian Y, Zhang L, Tian W, et al.

    Molecular cytogenetics 2018; (11()):49 doi:10.1186/s13039-018-0397-x.

    PMID: 30159034
  11. 11

    Confined placental mosaicism for 22q11.2 deletion as the etiology for discordant positive NIPT results.

    Bunnell M, Zhang C, Lee C, et al.

    Prenatal diagnosis 2017; (37(4)):416-419 doi:10.1002/pd.5022.

    PMID: 28198030
  12. 12

    Determining the origin of genome aberrations improves the positive predictive value of NIPT for 22q11.2 deletion syndrome.

    Xiang J, Sun X, Peng J, et al.

    Scientific reports 2025; (15(1)):24755 doi:10.1038/s41598-025-10446-8.

    PMID: 40634435
  13. 13

    Evaluation of pre-test counselling offered for non-invasive prenatal testing (NIPT) as a primary screening tool.

    Lee HYD, Chan LW

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2023; (43(1)):2204959 doi:10.1080/01443615.2023.2204959.

    PMID: 37154788
  14. 14

    NIPT of Maternal Plasma-Originated cfDNA: Applications and Guide for the Implementation.

    Fernández Martínez FJ, Gil Mira MM, González González C, et al.

    The application of clinical genetics 2025; (18()):41-53 doi:10.2147/TACG.S451444.

    PMID: 40321219
  15. 15

    Experiences of non-invasive prenatal screening: A survey study.

    Cornell P, Armstrong T, Fyfe R, et al.

    The Australian & New Zealand journal of obstetrics & gynaecology 2022; (62(2)):241-249 doi:10.1111/ajo.13436.

    PMID: 34570369
  16. 16

    Approach and Management of Pregnancies with Risk Identified by Non-Invasive Prenatal Testing.

    Gug M, Rațiu A, Andreescu N, et al.

    Journal of personalized medicine 2024; (14(4)) doi:10.3390/jpm14040366.

    PMID: 38672993
  17. 17

    Confined placental mosaicism is a diagnostic pitfall in dystrophinopathies: a clinical report.

    Sabbagh Q, Larrieux M, Schneider A, et al.

    European journal of human genetics : EJHG 2026; (34(1)):161-164 doi:10.1038/s41431-024-01665-0.

    PMID: 39014012
  18. 18

    Confined placental mosaicism of Duchenne muscular dystrophy: a case report.

    Winerdal M, Westenius E, Granfors M, et al.

    Molecular cytogenetics 2020; (13(1)):51 doi:10.1186/s13039-020-00520-3.

    PMID: 33334361
  19. 19

    Safety profile and risk factors of amniocentesis: evidence from a five-year single-centre retrospective study.

    Świetlicki A, Gutaj P, Iciek R, et al.

    BMC pregnancy and childbirth 2026; (26(1)).

    PMID: 41593530
  20. 20

    Case Report: Challenges of Non-Invasive Prenatal Testing (NIPT): A Case Report of Confined Placental Mosaicism and Clinical Considerations.

    Bonanni G, Trevisan V, Zollino M, et al.

    Frontiers in genetics 2022; (13()):881284 doi:10.3389/fgene.2022.881284.

    PMID: 35646091
  21. 21

    Experiences in microarray-based evaluation of developmental disabilities and congenital anomalies.

    Ozyilmaz B, Kirbiyik O, Koc A, et al.

    Clinical genetics 2017; (92(4)):372-379 doi:10.1111/cge.12978.

    PMID: 28128450
  22. 22

    Chromosomal Microarray Analysis as a First-Tier Clinical Diagnostic Test in Patients With Developmental Delay/Intellectual Disability, Autism Spectrum Disorders, and Multiple Congenital Anomalies: A Prospective Multicenter Study in Korea.

    Jang W, Kim Y, Han E, et al.

    Annals of laboratory medicine 2019; (39(3)):299-310 doi:10.3343/alm.2019.39.3.299.

    PMID: 30623622
  23. 23

    Reply.

    Jones KJ, Bevilacqua E, Grati FR, et al.

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2021; (58(4)):646 doi:10.1002/uog.24752.

    PMID: 34596305
  24. 24

    First trimester screening with biochemical markers and ultrasound in relation to non-invasive prenatal testing (NIPT).

    Scharf A

    Journal of perinatal medicine 2021; (49(8)):990-997 doi:10.1515/jpm-2021-0243.

    PMID: 34225389
  25. 25

    Prenatal vs postnatal diagnosis of 22q11.2 deletion syndrome: cardiac and noncardiac outcomes through 1 year of age.

    Freud LR, Galloway S, Crowley TB, et al.

    American journal of obstetrics and gynecology 2024; (230(3)):368.e1-368.e12 doi:10.1016/j.ajog.2023.09.005.

    PMID: 37717890
  26. 26

    Improved Outcomes in Patients with 22q11.2 Deletion Syndrome and Diagnosis of Interrupted Aortic Arch Prior to Birth Hospital Discharge, a Retrospective Study.

    Ron HA, Crowley TB, Liu Y, et al.

    Genes 2022; (14(1)) doi:10.3390/genes14010062.

    PMID: 36672801

This page is for informational purposes only and does not replace professional medical advice. Always consult your obstetrician, maternal-fetal medicine specialist, or genetic counselor to interpret your specific NIPT results and testing options.

Get notified when new evidence is published on 22q11.2 deletion syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.